Welcome to our dedicated page for BIOLASE news (Ticker: BIOL), a resource for investors and traders seeking the latest updates and insights on BIOLASE stock.
BIOLASE Inc. (BIOL) pioneers advanced laser solutions transforming dental care through minimally invasive technologies. This dedicated news hub provides investors and dental professionals with essential updates on product innovations, financial performance, and clinical developments.
Access real-time announcements including earnings reports, FDA clearances, partnership agreements, and technological breakthroughs. Our curated collection ensures transparent access to material events shaping BIOLASE's position in the $7B dental laser market.
Key updates cover regulatory milestones, patent filings, clinical trial results, and executive commentary. Discover how BIOLASE's Waterlase technology and Epic X platform continue redefining standards in laser dentistry through reduced recovery times and enhanced precision.
Bookmark this page for structured access to verified corporate communications. Monitor BIOLASE's progress in expanding global adoption of dental lasers while maintaining compliance with SEC disclosure requirements and medical device regulations.
BIOLASE, Inc. (NASDAQ: BIOL) reported a significant rebound in its third quarter 2020 results, with total revenue reaching $6.5 million, a 124% increase sequentially from Q2, although down 24% year over year. U.S. laser revenue rose 16% year over year to $2.7 million, driven by higher average selling prices. Operating expenses decreased by 24% to $5.9 million, leading to a reduced operating loss of $3.7 million. The company also strengthened its balance sheet via an $18 million equity raise, with cash reserves totaling $19.2 million as of September 30, 2020.
BIOLASE, Inc. (NASDAQ: BIOL) will announce its third quarter 2020 financial results on November 12, 2020, after U.S. market close. A conference call and webcast will take place at 4:30 p.m. ET to discuss the results. U.S./Canada participants can call (800) 367-2403, while international participants can dial +1 334-777-6978. The Conference ID is 9286776. A 30-day audio archive will be available afterward. BIOLASE specializes in dental laser systems, having sold over 41,500 units in over 80 countries, enhancing dental and medical practices.
BIOLASE, Inc. (NASDAQ: BIOL) has released an updated corporate presentation and business overview on M-Vest.com. This platform will serve as a regular update source for investors. The company's innovative laser systems have revolutionized dental practices, with over 41,200 units sold in more than 80 countries. BIOLASE emphasizes its extensive patent portfolio, which includes 261 patents and 52 patent-pending technologies aimed at enhancing patient care and recovery. For more details, visit www.biolase.com.
BIOLASE, Inc. (NASDAQ: BIOL) announced preliminary revenue results for Q3 2020, projecting revenues between $6.4 million to $6.6 million, a notable increase from Q2 2020. U.S. revenue is expected to match Q3 2019 levels as dentist practices reopen and resume operations amid the pandemic. Over 90% of U.S. laser revenue came from new Waterlase sales. The CEO highlighted that 95% of dental offices have reopened, with procedures at 70% of pre-pandemic levels. A webinar featuring dental experts will discuss the advantages of Waterlase technology.
BIOLASE, Inc. (NASDAQ: BIOL) announced an upcoming investor and analyst webinar on October 14, 2020, to showcase the benefits of laser dentistry and its role in reducing infection risks during the COVID-19 pandemic. With 85% of dental offices in the U.S. reopened and procedures at 70% of pre-COVID-19 levels, BIOLASE emphasizes its Waterlase Technology, which minimizes aerosolization by 98%. Esteemed dental experts will participate to discuss growth opportunities and share insights from the recently published McGuire study.
BIOLASE, Inc. (NASDAQ: BIOL) hosted a panel discussion with nearly 400 dental professionals to review a landmark study from the McGuire Institute. The study compared BIOLASE's REPAIR Perio laser protocol to traditional periodontal flap surgery for managing periodontitis. Key findings highlighted superior patient-related outcomes, including less bruising, swelling, and pain with laser treatment, in addition to faster procedure times. The event reflects growing enthusiasm in the dental community regarding laser treatments, indicating potential for future growth in BIOLASE's market presence.
BIOLASE, a leader in dental lasers, announced a presentation by Todd Norbe, President and CEO, and John Beaver, COO and CFO, at the H.C. Wainwright 22nd Annual Global Investor Conference on September 16, 2020, at 11:00 AM PT. The presentation will cover the company’s recent progress and achievements and will include virtual one-on-one meetings with institutional investors. The live webcast can be accessed at this link or on BIOLASE's investor relations website, showcasing their innovative dental technology.
BIOLASE, Inc. (NASDAQ: BIOL) will present an overview of the company and its recent progress at the Colliers & Co. Institutional Investor Conference on September 10, 2020. Executives Todd Norbe and John Beaver will engage in virtual meetings with institutional investors. Norbe expressed optimism regarding BIOLASE's positioning for growth post-COVID-19, citing enthusiasm for recent study results on Waterlase-assisted treatment of periodontitis. BIOLASE has sold over 41,200 dental laser systems globally, leveraging 261 patented and 52 patent-pending technologies to improve dental procedures.
Foothill Ranch, CA / ACCESSWIRE / August 24, 2020 - BIOLASE, Inc. (NASDAQ:BIOL) announced that President and CEO Todd Norbe and CFO John Beaver will present at the LD Micro 500 virtual conference on September 3, 2020, at 1:40 PM PT. Investors can also schedule one-on-one meetings from September 1-3.
The conference runs from September 1-4 and showcases updates from 500 prominent micro-cap companies. The presentation will be accessible via BIOLASE's investor relations page. For more details, visit www.biolase.com.
BIOLASE, Inc. (NASDAQ: BIOL) announced it has regained compliance with Nasdaq's minimum stockholders' equity requirement of $2.5 million after an $18 million Rights Offering. Nasdaq granted an additional 180-day grace period for the company to meet the $1.00 minimum bid price requirement, expiring on February 16, 2021. CFO John Beaver has been promoted to Chief Operating Officer, maintaining his financial duties. The company's laser systems support safe dental practices amid the COVID-19 pandemic, producing 98% less aerosols than traditional methods.
FAQ
What is the current stock price of BIOLASE (BIOL)?
What is the market cap of BIOLASE (BIOL)?
